Get the Daily Brief
Latest Biotech News
Roche’s breast‑cancer pill fails first‑line Phase 3 — Program setback
Roche reported a failure in a pivotal Phase 3 first‑line trial for its oral breast‑cancer candidate, undercutting expectations that the drug could become a major revenue driver. The company said...
Daraxonrasib posts high responses — Moves toward Phase 3 in RAS‑mutant pancreatic cancer
Revolution Medicines reported daraxonrasib produced objective response rates of 47–55% in early cohorts of RAS‑mutant metastatic pancreatic ductal adenocarcinoma (PDAC), outperforming historical...
DNA‑repair mutations modulate pancreatic cancer response — Treatment stratification insight
New research identified DNA‑repair gene alterations as modifiers of response to combination chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC). The study examined how defects in...
New resistance pathways mapped for lenacapavir — HIV drug under evolutionary pressure
Researchers published findings in Nature Communications mapping recurring and novel evolutionary routes by which HIV‑1 acquires resistance to lenacapavir, a long‑acting capsid inhibitor. The work...
High‑throughput DnD assay exposes hidden antibiotic resistance — Diagnostic leap
A team led by Ma and Kim unveiled the dilution‑and‑delay (DnD) susceptibility assay in Nature Communications, a high‑resolution, high‑throughput method that uncovers cryptic antibiotic resistances...
Wireless retinal implant restores reading for geographic atrophy patients
Clinical researchers reported that a wireless subretinal implant (PRIMA) restored functional central vision in patients with late‑stage geographic atrophy from age‑related macular degeneration. In...
MRI‑steered catheter and mid‑IR fiber probe — New tools for real‑time tissue access and monitoring
Two independent device advances promise finer intraprocedural control and noninvasive biochemical sensing. A concentric‑tube catheter steered under MRI guidance enables precise endoluminal...
PPQ strategies for cell and gene therapies — Preventing quality and compliance setbacks
Quality lifecycle planning for process performance qualification (PPQ) remains a critical bottleneck for cell and gene therapy developers. Guidance and case studies highlight common failure...
uniQure-FDA standoff: agency presses for sham-surgery trial
The FDA escalated scrutiny of uniQure’s AMT‑130 Huntington’s disease gene therapy by urging a prospective, randomized, double‑blind, sham‑surgery‑controlled trial, prompting fierce public dispute...
Roche’s pivotal miss — breast‑cancer pill fails first‑line trial
Roche announced that its oral breast‑cancer candidate failed a crucial Phase 3 first‑line study, dashing expectations that the drug could become a major revenue driver. The company had previously...
Daraxonrasib posts 47% ORR — Revolution targets Phase 3 in RAS PDAC
Revolution Medicines reported daraxonrasib produced a 47% objective response rate (ORR) in a treatment‑naïve cohort of RAS‑mutant metastatic pancreatic ductal adenocarcinoma (PDAC), prompting...
Wireless eye implant... blind patients read again
A wireless subretinal implant (PRIMA) restored functional central vision in a clinical study of patients with geographic atrophy, enabling reading of short words and numbers after years of...
Petrelintide meets endpoints — but weight loss lags expectations
Roche and Zealand Pharma reported Phase 2 results for petrelintide, an amylin receptor‑targeting peptide, meeting trial endpoints with tolerability comparable to placebo but producing average...
Study maps new HIV‑1 resistance routes to lenacapavir
Researchers published novel pathways by which HIV‑1 can evolve resistance to lenacapavir, a long‑acting capsid inhibitor, documenting recurrent and unique mutational routes in Nature...
High‑throughput DnD assay reveals hidden antibiotic resistances
A team led by Ma and Kim published a dilution‑and‑delay (DnD) susceptibility assay in Nature Communications that detects low‑frequency or time‑dependent antibiotic resistance missed by standard...
ITK targeting ramps up anti‑CD19 CAR‑T potency
Researchers disclosed that targeting interleukin‑2‑inducible T‑cell kinase (ITK) enhances the efficacy of anti‑CD19 CAR‑T cells by remodeling T‑cell signaling and function. The preclinical work...
DNA‑repair defects alter chemotherapy outcomes in metastatic PDAC
New research links DNA repair gene alterations to differential efficacy of combination chemotherapies in metastatic pancreatic ductal adenocarcinoma (PDAC). The study shows that tumors with...
Video AI quantifies Parkinson’s finger‑tapping motor signs
Researchers introduced a video‑based system that quantifies finger‑tapping performance in Parkinson’s disease using interpretable computer vision and machine‑learning readouts. The tool delivers...
uniQure and FDA... Sham-surgery demand fuels stock roller-coaster
uniQure’s experimental Huntington’s gene therapy AMT-130 remains at the center of an escalating regulatory standoff with the U.S. Food and Drug Administration. The FDA signaled that data from...
Daraxonrasib... 47–55% ORR pushes RAS drug toward Phase 3
Revolution Medicines’ daraxonrasib (RMC-6236) produced objective response rates near 47% in a first-line cohort of RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC), according to...